Taiwanese collagen medical device manufacturer Horien Biochemical Technology (7814) officially listed on the OTC market today (July 16). Horien Biochemical Technology has attracted significant attention from the capital market due to its recent outstanding performance in revenue, international certifications, global market expansion, and the establishment of a top-tier biomedical raw material supply chain. The underwriting price was NT$28.47, and the stock price opened at NT$32, a gain of over 12%.

 On July 7, Horien Biochemical Technology successfully obtained three high-risk (highest level, Class 4) medical device market licenses in Thailand, successfully entering the high-end medical device market in ASEAN. Furthermore, it is expected to obtain Class III medical device licenses in the Philippines and Vietnam soon, signifying that its important strategic layout in the Southeast Asian market is nearing completion. In addition, Haichang's highly anticipated bio-ink innovative product is planned to be officially exported to the European market by the end of this year, extending its international footprint from Asia to Europe and America.

 In the research and development of advanced innovative medical devices, Horien Biotech's independently developed "biodegradable ureteral stent" has successfully obtained a Taiwanese invention patent and is expected to soon secure invention patents in the United States, Europe, and China. Currently, this innovative product has successfully completed sample development and has been officially delivered for animal testing. As no other company in the industry has yet obtained relevant medical device certifications, Horien Biotech is at the forefront globally.

 Horien Biotech Chairman Tsai Kuo-Tien stated that the successful listing on the OTC market is a significant milestone in Horien Biotech's development history. In the future, the company will continue to deepen its global market penetration by leveraging top-grade medical-grade raw materials and groundbreaking advanced medical device drugs, building upon its existing dental and surgical channels. With the acquisition of international certifications and the harvesting phase of its innovative product lines, Horien Biotech will create maximum value for all shareholders and the Taiwanese biotechnology industry through steady and rapid growth.

Report link:
"Liberty Times" Focus Stock: Horien Biochemical Technology: Shares Soar on First Day of Listing; Southeast Asian High-End Medical Devices Strategy Taking Shape
Liberty Times / Chen Yung-Chi